BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. Oncogenic Signaling Induced by HCV Infection. Viruses 2018;10:E538. [PMID: 30279347 DOI: 10.3390/v10100538] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Lohmann V, Bartenschlager R. Indelibly Stamped by Hepatitis C Virus Infection: Persistent Epigenetic Signatures Increasing Liver Cancer Risk. Gastroenterology 2019;156:2130-3. [PMID: 31034828 DOI: 10.1053/j.gastro.2019.04.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gal-tanamy M. Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running. Gastroenterology 2019;157:300-2. [DOI: 10.1053/j.gastro.2019.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Borsetto D, Fussey J, Fabris L, Bandolin L, Gaudioso P, Phillips V, Polesel J, Boscolo-Rizzo P. HCV infection and the risk of head and neck cancer: A meta-analysis. Oral Oncol 2020;109:104869. [PMID: 32599500 DOI: 10.1016/j.oraloncology.2020.104869] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Huang XB, He YG, Zheng L, Feng H, Li YM, Li HY, Yang FX, Li J. Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network. World J Gastroenterol 2019; 25(33): 4921-4932 [PMID: 31543683 DOI: 10.3748/wjg.v25.i33.4921] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Baumert TF, Hoshida Y. Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma. Viruses 2019;11:E441. [PMID: 31096600 DOI: 10.3390/v11050441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
6 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Valiakou V, Eliadis P, Karamichali E, Tsitsilonis O, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. Int J Mol Sci 2021;22:7961. [PMID: 34360721 DOI: 10.3390/ijms22157961] [Reference Citation Analysis]
9 Scott TA, Morris KV. Designer nucleases to treat malignant cancers driven by viral oncogenes. Virol J 2021;18:18. [PMID: 33441159 DOI: 10.1186/s12985-021-01488-1] [Reference Citation Analysis]